Drug intelligence / Profile preview

AFX-593

Development stage: Preclinical
Lead developer: Afecta Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

AFX-593 is a small molecule therapeutic candidate being developed by Afecta Pharmaceuticals for the treatment of diabetic retinopathy. It is designed to address intraocular dysmetabolosis (metabolic dysregulation within the eye) and inhibit the activation of pro-inflammatory microglia. By targeting these underlying pathological processes, AFX-593 aims to mitigate the neurovascular damage associated with diabetic retinopathy. As of the latest pipeline information, the drug is in late-stage preclinical development.

Targets

CCL2 (C-C motif chemokine 2)CCL5 (C-C Motif Chemokine Ligand 5)

Beyond the preview

Go deeper on AFX-593.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFX-593.

Explore the full profile